Suicide, suicidality and suicide prevention in affective disorders

Acta Psychiatrica Scandinavica, Supplement

Volumn 108, Issue 418, 2003, Pages 73-80

  Moller H J ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Bipolar affective disorder; Suicidality; Suicide; Suicide prevention; Unipolar affective disorder

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; LITHIUM; PAROXETINE; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; ZIMELDINE; MAPROTILINE; MIANSERIN; MOOD STABILIZER; PLACEBO; TRICYCLIC ANTIDEPRESSANT AGENT;

CLINICAL TRIAL; CONFERENCE PAPER; EPIDEMIOLOGICAL DATA; HUMAN; INCIDENCE; MOOD DISORDER; PSYCHOPHARMACOLOGY; PSYCHOTHERAPY; RISK ASSESSMENT; RISK FACTOR; SOCIAL PSYCHIATRY; SOCIAL PSYCHOLOGY; SUICIDAL BEHAVIOR; SUICIDE; SUICIDE ATTEMPT; BIPOLAR DISORDER; DISEASE PREDISPOSITION; MANIA; META ANALYSIS; PRIORITY JOURNAL; PROPHYLAXIS; SYSTEMATIC REVIEW;

EID: 0141740484     PISSN: 00651591     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0447.108.s418.15.x     Document Type: Conference Paper

References (84)

1. HARRIS EC, BARRACLOUGH B. Excess mortality of mental disorder. Br J Psychiatry 1998;173:11-53.
2. WHO. Euro multicentre study on parasuicide. Facts and figures. Copenhagen: WHO Regional Office for Europe, 1999.
3. SCHMIDTKE A, WEINACKER B, APTER A et al. Suicide rates in the world: Update, Arch Suicide Res 1999;5:81-89.
4. GUZE SB, ROBINS E. Suicide and primary affective disorders. Br J Psychiatry 1970;117:437-438.
5. MÖLLER HJ, GRUNZE H. Have some guidelines for the treatment of acute bipolar depression gone too far in the restriction of antidepressants? Eur Arch Psychiatry Clin Neurosci 2000;250:57-68.
6. INSKIP HM, HARRIS EC, BARRACLOUGH B. Lifetime risk of suicide for affective disorder, alcoholism and schizophrenia. Br J Psychiatry 1998;172:35-37.
7. HARRIS EC, BARRACLOUGH B. Suicide as an outcome for mental disorders. A meta-analysis. Br J Psychiatry 1997;170:205-228.
8. SIMPSON SG, JAMISON KR. The risk of suicide in patients with bipolar disorders. J Clin Psychiatry 1999;60:53-56.
9. LESTER D. Suicidal behavior in bipolar and unipolar affective disorders: a meta-analysis. J Affect Disord 1993;27:117-121.
10. BLACK DW, WINOKUR G, NASRALLAH A. Effect of psychosis on suicide risk in 1,593 patients with unipolar and bipolar affective disorders. Am J Psychiatry 1988;145:849-852.
11. ANGST J, FELDER W, FREY R. The course of unipolar and bipolar affective disorder. In: SCHOU M, STROMGEN E, eds. Origin, prevention and treatment of affective disorders. London: Academic Press, 1979:215-226.
12. MCGLASHAN TH. The Chestnut Lodge follow-up study. II. Long-term outcome of schizophrenia and the affective disorders. Arch Gen Psychiatry 1984;41:586-601.
13. MARTIN RL, CLONINGER CR, GUZE SB, CLAYTON PJ. Mortality in a follow-up of 500 psychiatric outpatients. II. Cause-specific mortality. Arch Gen Psychiatry 1985;42:58-66.
14. WINOKUR G, BLACK DW. Psychiatric and medical diagnoses as risk factors for mortality in psychiatric patients: a case-control study. Am J Psychiatry 1987;144:208-211.
15. DUNNER DL, GERSHON ES, GOODWIN FK. Heritable factors in the severity of affective illness. Biol Psychiatry 1976;11:31-42.
16. MORRISON JR. Suicide in a psychiatric practice population. J Clin Psychiatry 1982;43:348-352.
17. FAWCETT J, SCHEFTNER W, CLARK D, HEDEKER D, GIBBONS R, CORYELL W. Clinical predictors of suicide in patients with major affective disorders: a controlled prospective study. Am J Psychiatry 1987;144:35-40.
18. TSUANG MT. Suicide in schizophrenics, manics, depressives, and surgical controls. A comparison with general population suicide mortality. Arch Gen Psychiatry 1978;35:153-155.
19. PERRIS C, D'ELIA G. A study of bipolar (manic-depressive) and unipolar recurrent depressive psychoses. X. Mortality, suicide and life-cycles. Acta Psychiatr Scand 1966;42(Suppl. 94):172-189.
20. WEEKE A, VAETH M. Excess mortality of bipolar and unipolar manic-depressive patients. J Affect Dis 1986;11:227-234.
21. GOODWIN FK, JAMISON KR. Manic-depressive illness. New York: Oxford University Press, 1990.
22. CHEN YW, DILSAVER SC. Lifetime rates of suicide attempts among subjects with bipolar and unipolar disorders relative to subjects with other Axis 1 disorders. Biol Psychiatry 1996;39:896-899.
23. CORYELL W, ANDREASEN NC, ENDICOTT J, KELLER M. The significance of past mania or hypomania in the course and outcome of major depression. Am J Psychiatry 1987;144:309-315.
24. MCGLASHAN TH. The Chestnut Lodge follow-up study. I. Follow-up methodology and study sample. Arch Gen Psychiatry 1984;41:573-585.
25. BOTTLENDER R, JÄGER M, STRAUSS A, MÖLLER HJ. Suicidality in bipolar compared to unipolar depressed inpatients. Eur Arch Psychiatry Clin Neurosci 2000;250:257-261.
26. DILSAVER SC, CHEN YW, SWANN AC, SHOAIB AM, KRAJEWSKI KJ. Suicidality in patients with pure and depressive mania. Am J Psychiatry 1994;151:1312-1315.
27. ISOMETSA ET, HENRIKSSON MM, ARO HM, LONNQVIST JK. Suicide in bipolar disorder in Finland. Am J Psychiatry 1994;151:1020-1024.
28. ROY A, NIELSEN D, RYLANDER G, SARCHIAPONE M, SEGAL N. Genetics of suicide in depression. J Clin Psychiatry 1999;60:212-217.
29. STATHAM DJ, HEATH AC, MADDEN PA. Suicidal behaviour: an epidemiological and genetic study. Psychol Med 1998;28:839-855.
30. LIDBERG L, BELFRAGE H, BERTILSSON L, EVENDEN MM, ASBERG M. Suicide attempts and impulse control disorder are related to low cerebrospinal fluid 5-HIAA in mentally disordered violent offenders. Acta Psychiatr Scand 2000;101:395-402.
31. ASBERG M. Neurotransmitters and suicidial behavior. The evidence from cerebrospinal fluid studies. Ann NY Acad Sci 1997;836:158-181.
32. MANN JJ, MALONE KM, NIELSEN DA, GOLDMAN D, ERDOS J, GELERNTER J. Possible association of a polymorphism of the tryptophan hydroxylase gene with suicidal behavior in depressed patients. Am J Psychiatry 1997;154:1451-1453.
33. LINNOILA M, VIRKKUNEN M. Biologic correlates of suicidal risk and aggressive behavioral traits. J Clin Psychopharmacol 1992;12:19S-20S.
34. VIRKKUNEN M, LINNOILA M. Psychobiology of violent behavior. Clin Neuropharmacol 1992;15:233A-234A.
35. KURZ A, TORHORST A, WACHTLER C, MÖLLER HJ. Vergleichende Untersuchung von 295 Patienten mit erstmaligem und wiederholtem Suizidversuch [Comparative study of 295 patients with first and repeated suicide attempts]. Arch Psychiatr Nervenkr 1982;232:427-438.
36. KURZ A, MÖLLER HJ, BAINDL G. Classification of parasuicide by cluster analysis. Types of suicidal behaviour, therapeutic and prognostic implications. Br J Psychiatry 1987;150:520-525.
37. TORHORST A, MÖLLER HJ, KURZ A, SCHMID-BODE W, LAUTER H. Comparing a 3-month- and a 12-month-outpatient aftercare program for parasuicide repeaters. In: MÖLLER HJ, SCHMIDTKE A, WELZ R, eds. Current issues of suicidology. Berlin: Springer, 1988:419-424.
38. ISOMETSA E, HEIKKINEN M, HENRIKSSON M, ARO H, LONNQVIST J. Recent life events and completed suicide in bipolar affective disorder. A comparison with major depressive suicides. J Affect Dis 1995;33:99-106.
39. RUTZ W. Preventing suicide and premature death by education and treatment. J Affect Dis 2001;62:123-129.
40. ALTHAUS D, HEGERL U. Evaluation suizidpräventiver Maßnahmen. Aktueller Forschungsstand und resultierende Implikationen. Nervenarzt 2001;72:677-684.
41. ISACSSON G. Suicide prevention - a medical breakthrough? Acta Psychiatr Scand 2000;102:113-117.
42. MÖLLER HJ. Suizidalität unter Antidepressivabehandlung. In: WOLFERSDORF M, KASCHKA WP, eds. Suizidalität - die Biologische Dimension. Tropon-Symposium, Vol. X. Berlin: Springer-Verlag, 1995:129-139.
43. MONTGOMERY S, CRONHOLM B, ASBERG M, MONTGOMERY DB. Differential effects on suicidal ideation of mianserin, maprotiline and amitriptyline. Br J Clin Pharmacol 1978;5:77S-80S.
44. KAHN A, WARNER HA, BROWN WA. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials, an analysis of the Food and Drug Administration database. Arch Gen Psychiatry 2000;57:311-317.
45. ISACSSON G, BERGMAN U, RICH CL. Antidepressants, depression and suicide: an analysis of the San Diego study. J Affect Dis 1994;32:277-286.
46. ISACSSON G, HOLMGREN P, DRUID H, BERGMAN U. Psychotropics and suicide prevention. Implications from toxicological screening of 5281 suicides in Sweden 1992-94. Br J Psychiatry 1999;174:259-265.
47. ISACSSON G, BERGMAN U, RICH CL. Epidemiological data suggest antidepressants reduce suicide risk among depressives. J Affect Dis 1996;41:1-8.
48. RUTZ W, VON KNORRING L, WALINDER J. Frequency of suicide on Gotland after systematic postgraduate education of general practitioners. Acta Psychiatr Scand 1989;80:151-154.
49. RUTZ W, WALINDER J, EBERHARD G et al. An educational program on depressive disorders for general practitioners on Gotland: background and evaluation. Acta Psychiatr Scand 1989;79:19-26.
50. ASBERG M, NORDSTRÖM P. Biological correlates of suicidal behaviour. In: MÖLLER HJ, SCHMIDTKE A, WELZ R, eds. Current issues of suicidology. Berlin: Springer, 1988:221-241.
51. TRASKMAN L, ASBERG M, BERTILSSON L, SJOSTRAND L. Monoamine metabolites in CSF and suicidal behavior. Arch Gen Psychiatry 1981;38:631-636.
52. MONTGOMERY SA, MCAULEY R, RANI SJ, ROY D, MONTGOMERY DB. A double blind comparison of zimelidine and amitriptyline in endogenous depression. Acta Psychiatr Scand 1981;290:314-327.
53. AMIN MM, ANANTH JV, COLEMAN BS et al. Fluvoxamine antidepressant effects confirmed in a placebo-controlled international study. Clin Neuropharmacol 1984;7:580-581.
54. MÖLLER HJ, STEINMEYER EM. Are serotonergic reuptake inhibitors more potent in reducing suicidality? An empirical study on paroxetine. Eur Neuropsychopharmacol 1994;4:55-59.
55. MONTGOMERY SA, DUNNER DL, DUNBAR GC. Reduction of suicidal thoughts with paroxetine in comparison with reference antidepressants and placebo. Eur Neuropsychopharmacol 1995;5:5-13.
56. BEASLEY C-M, DORNSEIF BE, BOSOMWORTH JC et al. Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. Br Med J 1991;303:685-692.
57. WAKELIN JS. The role of serotonin in depression and suicide: do serotonin reuptake inhibitors provide a key? In: MENDLEWITCZ JH, VAN PRAAG M, eds. Advances in biological psychiatry, Vol. 17. Basel: Karger, 1988:70-83.
58. SACCHETTI E, VITA A, GUARNERI L, CORNACCHIA M. The effectiveness of fluoxetine, clomipramine, nortriptyline and desipramine in major depressives with suicidal behaviour: preliminary findings. In: CASSANO GB, AKISKAL HS, eds. Serotonin-related psychiatric syndromes: clinical and therapeutic links. Royal Society of Medicine Services International Congress and Symposium Series 165, 1991:105-113.
59. MÜLLER-OERLINGHAUSEN B, MUSER CB, VOLK J. Suicides and parasuicides in a high-risk patient group on and off lithium long-term medication. J Affect Dis 1992;25:261-269.
60. TONDO L, BALDESSARINI RJ, HENNEN J, FLORIS G, SILVETTO F, TOHEN M. Lithium treatment and risk of suicidal behavior in bipolar disorder patients. J Clin Psychiatry 1998;59:405-414.
61. MÜLLER-OERLINGHAUSEN B, WOLF T, AHRENS B et al. Mortality of patients who dropped out from regular lithium prophylaxis: a collaborative study by the International Group for the Study of Lithium-treated patients (IGSLI). Acta Psychiatr Scand 1996;94:344-347.
62. BALDESSARINI RJ, TONDO L, HENNEN J. Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar manic-depressive disorders. J Clin Psychiatry 1999;60:77-84.
63. TONDO L, HENNE J, BALDESSARINI RJ. Lower suicide risk with long-term lithium treatment in major affective illness: a meta-analysis. Acta Psychiatr Scand 2001;104:163-172.
64. MÜLLER-OERLINGHAUSEN B. Pharmakotherapie pathologischen aggressiven und autoaggressiven Verhaltens. In: PÖLDINGER W, WAGNER W, eds. Aggression, Selbstaggression, Familie und Gesellschaft. Berlin: Springer, 1989:121-134.
65. COPPEN A, STANDISH-BARRY H, BAILEY J, HOUSTON G, SILCOCKS P, HERMON C. Does lithium reduce the mortality of recurrent mood disorders? J Affect Dis 1991;23:1-7.
66. SCHRAUZER GN, SHRESTHA KP. Lithium in drinking water and the incidences of crimes, suicides, and arrests related to drug addictions. Biol Trace Elem Res 1990;25:105-113.
67. THIES-FLECHTNER K, MÜLLER-OERLINGHAUSEN B, SEIBERT W, WALTHER A, GREIL W. Effect of prophylactic treatment on suicide risk in patients with major affective disorders. Data from a randomized prospective trial. Pharmacopsychiatry 1996;29:103-107.
68. SCHOU M, WEEKE A. Did manic-depressive patients who committed suicide receive prophylactic or continuation treatment at the time? Br J Psychiatry 1988;153:324-327.
69. RIHMER Z, BARSI J, ARATO M, DEMTER E. Suicide in subtypes of primary major depression. J Affect Dis 1990;18:221-225.
70. ANDERSEN UA, ANDERSEN M, ROSHOLM JU, GRAM LF. Psychopharmacological treatment and psychiatric morbidity in 390 cases of suicide with special focus on affective disorders. Acta Psychiatr Scand 2001;104:458-465.
71. HENRIKSSON S, BOETHUIS G, ISACSSON G. Suicides are seldom prescribed antidepressants: findings from a prospective prescription database in Jamtland county, Sweden, 1985-95. Acta Psychiatr Scand 2001;103:301-306.
72. LEPINE JP, GASTPAR M, MENDLEWICZ J, TYLEE A. Depression in the community: the first pan-European study DEPRES (Depression Research in European Society). Int Clin Psychopharmacol 1997;12:19-29.
73. LINDEN M, MAIER W, ACHBERGER M, HERR R, HELMCHEN H, BENKERT O. Psychische Erkrankungen und ihre Behandlung in Allgemeinarztpraxen in Deutschland. Ergebnisse aus einer Studie der Weltgesundheitsorganisation (WHO). [Psychiatric diseases and their treatment in general practice in Germany. Results from a World Health Organization (WHO) study]. Nervenarzt 1996;67:205-215.
74. VASSILAS CA, MORGAN HG. General practitioners' contact with victims of suicide. Br Med J 1993;307:300-301.
75. TEICHER MH, GLOD C, COLE JO. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 1990;147:207-210.
76. CALLAHAN CM, HENDRIE HC, DITTUS RS, BRATER DC, HUI SL, TIERNEY WM. Improving treatment of late life depression in primary care: a randomized clinical trial. J Am Geriatr Soc 1994;42:839-846.
77. THOMPSON C, KINMONTH AL, STEVENS L et al. Effects of a clinical-practice guideline and practice-based education on detection and outcome of depression in primary care: Hampshire Depression Project randomised controlled trial. Lancet 2000;355:185-191.
78. MURPHY GE, CARNEY RM, KNESEVICH MA, WETZEL RD, WHITWORTH P. Cognitive behavior therapy, relaxation training, and tricyclic antidepressant medication in the treatment of depression. Psychol Rep 1995;77:403-420.
79. THASE ME, SIMONS AD, CAHALANE J, MCGEARY J, HARDEN T. Severity of depression and response to cognitive behavior therapy. Am J Psychiatry 1991;148:784-789.
80. SALKOVSKIS PM, ATHA C, STORER D. Cognitive-behavioural problem solving in the treatment of patients who repeatedly attempt suicide. A controlled trial. Br J Psychiatry 1990;157:871-876.
81. MOTTO JA. Suicide prevention for high-risk persons who refuse treatment. Suicide Life Threat Behav 1976;6:223-230.
82. MOTTO J, HEILBRON D, JUSTER R, BOSTROM A. Communication as a suicide prevention programme. In: SOUBRIER JP, VEDRINNE J, eds. Depression et suicide. Paris: Pergamon, 1981:148-154.
83. MORGAN HG, JONES EM, OWEN JH. Secondary prevention of non-fatal deliberate self-harm. The green card study. Br J Psychiatry 1993;163:111-112.
84. DE LEO D, CAROLLO G, DELLO-BUONO M. Lower suicide rates associated with a Tele-Help/Tele-Check service for the elderly at home. Am J Psychiatry 1995;152:632-663.